Free Trial
NASDAQ:FNCH

Finch Therapeutics Group (FNCH) Stock Price, News & Analysis

Finch Therapeutics Group logo
$11.95
-0.20 (-1.65%)
(As of 11/4/2024 ET)

About Finch Therapeutics Group Stock (NASDAQ:FNCH)

Key Stats

Today's Range
$11.95
$12.10
50-Day Range
$11.00
$13.69
52-Week Range
$0.80
$14.26
Volume
1,026 shs
Average Volume
5,408 shs
Market Capitalization
$19.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Receive FNCH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Finch Therapeutics Group and its competitors with MarketBeat's FREE daily newsletter.

FNCH Stock News Headlines

Finch Therapeutics announces Nasdaq delisting, SEC deregistration
Top 10 AI Stocks to Buy Now
Are you ready to capitalize on the booming AI market? Our experts have identified the top 10 AI stocks set to skyrocket.
Finch Therapeutics Group to Delist from Nasdaq
Finch Therapeutics Group (NASDAQ: FNCH)
See More Headlines

FNCH Stock Analysis - Frequently Asked Questions

Finch Therapeutics Group's stock was trading at $3.61 at the start of the year. Since then, FNCH shares have increased by 231.0% and is now trading at $11.95.
View the best growth stocks for 2024 here
.

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) posted its quarterly earnings results on Tuesday, August, 13th. The company reported ($3.01) EPS for the quarter.

Finch Therapeutics Group shares reverse split on the morning of Monday, June 12th 2023. The 1-30 reverse split was announced on Monday, June 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Finch Therapeutics Group (FNCH) raised $101 million in an initial public offering on Friday, March 19th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI acted as the underwriters for the IPO.

Shares of FNCH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Finch Therapeutics Group investors own include CNS Pharmaceuticals (CNSP), Faraday Future Intelligent Electric (FFIE), Allarity Therapeutics (ALLR), Aridis Pharmaceuticals (ARDS), Meta Platforms (META), NVIDIA (NVDA) and Altamira Therapeutics (CYTO).

Company Calendar

Last Earnings
8/13/2024
Today
11/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:FNCH
Fax
N/A
Employees
190
Year Founded
N/A

Profitability

Net Income
$-74,750,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$110,000.00
Book Value
$14.25 per share

Miscellaneous

Free Float
885,000
Market Cap
$19.24 million
Optionable
No Data
Beta
1.34
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:FNCH) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners